Addition of daptomycin for the treatment of pneumococcal meningitis: protocol for the AddaMAP study.
Fiche publication
Date publication
juillet 2023
Journal
BMJ open
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BINQUET Christine, Dr FOURNEL Isabelle
Tous les auteurs :
Chavanet P, Fournel I, Bourredjem A, Piroth L, Blot M, Sixt T, Binquet C
Lien Pubmed
Résumé
The leading cause of acute bacterial meningitis in adults is . This infection is associated with high rates of mortality and morbidity related, among other factors, to the excessive host response to the pneumococcal lysis. Experimental in vitro and in vivo data show that the combination of corticosteroids/third-generation cephalosporins and the non-lytic antibiotic, daptomycin, has synergistic effects with (1) a rapid cerebrospinal fluid sterilisation, (2) less brain damages and (3) less loss of cognitive performances. Despite these encouraging results, daptomycin has never been evaluated in adult patients with pneumococcal meningitis.
Mots clés
adult intensive & critical care, clinical trial, clinical trials, infectious diseases, microbiology
Référence
BMJ Open. 2023 07 25;13(7):e073032